Altimmune Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Altimmune Inc in the market include companies such as Inovio Pharmaceuticals, VBI Vaccines, Novavax, and Moderna Inc.

Altimmune Inc is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. Founded in 1997, Altimmune has a rich history of innovation in the field of immunology. The company specializes in the development of novel vaccines and immune-modulating therapies to combat infectious diseases. Altimmune's proprietary platform technologies enable the rapid design and development of next-generation immunotherapies. With a strong commitment to scientific research and development, Altimmune aims to transform the treatment landscape by addressing unmet medical needs. With its experienced team and extensive portfolio, Altimmune Inc is poised to make a significant impact on the global healthcare industry.

Altimmune Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include the successful completion of Phase 2 clinical trials for its lead product candidate, AdCOVID, a single-dose intranasal COVID-19 vaccine. The company has also demonstrated the effectiveness of NasoShield, a vaccine for anthrax, in preclinical studies. Altimmune Inc has further enhanced its portfolio by acquiring Spitfire Pharma, a biopharmaceutical company focused on liver diseases. Additionally, the company has established collaborations with leading organizations, including the University of Alabama and the National Institutes of Health, to advance its innovative pipeline. These milestones highlight Altimmune Inc's dedication to advancing novel therapies and its potential for future growth in the biopharmaceutical industry.

Altimmune Inc is primarily present in the United States.

Altimmune Inc represents a core value of innovation and commitment to transformative medical solutions. With a strong corporate philosophy focused on advancing novel therapies, Altimmune Inc continuously strives to improve patient outcomes through groundbreaking immunotherapies. The company's dedication to scientific excellence and rigorous research enables the development of cutting-edge vaccine candidates, including intranasal vaccines to combat infectious diseases. Altimmune Inc's vision encompasses pioneering approaches in immunology and the goal of addressing unmet medical needs worldwide. By leveraging its expertise, Altimmune Inc remains at the forefront of medical advancements, exemplifying a steadfast commitment to improving global health.

Analysts currently set an average price target of 18,67 USD for the Altimmune stock (median: 20,40 USD), implying +502,1 % versus the latest price. The consensus is based on 15 analyst ratings.

Altimmune Analytikerens Kursmål 2026

15 analysts currently rate the Altimmune stock: 12 recommend buying, 2 holding and 1 selling.

Altimmune Analytikerens Kursmål 2026

Converted at the current exchange rate, the Altimmune share trades at 2,66 EUR (3,10 USD).

The Altimmune share (ALT) is listed on 5 stock exchanges, including: NASDAQ (ALT), Frankfurt (3G0.F), München (3G0.MU), Düsseldorf (3G0.DU), London (0A4C.L).

The company Altimmune Inc. is a biopharmaceutical company specializing in the development of immunotherapies and vaccines for various diseases. Its business model is based on innovative research and development to meet the increasingly complex challenges of the medical industry. The company operates in three business areas - Immundevelopment, Vaxine, and Altimmune UK. Immundevelopment focuses on the research of immunotherapies and viral infections such as hepatitis B, HIV, and influenza. Vaxine develops vaccines against flu, anthrax, MERS, RSV, and COVID-19. Altimmune UK is increasingly focused on the field of neuroscience and oncology. Altimmune is divided into two pillars, immunotherapy and vaccine development. The two pillars work closely together to accelerate and improve the development of therapies and vaccines. In the immunotherapy pillar, treatments are being researched that stimulate the immune system to fight against various diseases. In the vaccine development, Altimmune produces vaccines that induce active immunization against certain diseases. One of Altimmune's most important products is NasoVAX, an intranasally administered flu vaccine. Compared to conventional injectable vaccines, NasoVAX offers faster action and does not require a nurse. NasoShield, an intranasally administered anthrax vaccine, is another well-known product from Altimmune. The company has also developed COVID-19 vaccine candidates that are now being tested in clinical trials. Altimmune aims to develop innovative solutions for serious diseases. The company has a strong commitment to research and development and is committed to continuing its successes in drug development. The company's mission is to ensure the creation of cost-effective solutions and improvement of outcomes for patients. Through the development of novel therapies and vaccines, Altimmune is repeatedly praised as one of the most promising companies in the industry. With a growing product range and a strong research and development department, the company is well-equipped to tackle important medical challenges of the future. In the future, it will be of great importance for Altimmune to continue developing innovative products that meet medical requirements. The industry will evolve through new scientific discoveries and the use of cutting-edge technologies, and Altimmune strives to play a leading role in this transformation.

Omsætningen kan for øjeblikket ikke beregnes for Altimmune.

forventet-overskuddet for Altimmune er -40,71 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Altimmune er i øjeblikket -7,66. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Altimmune-aktien.

P/S-forholdet kan ikke beregnes for Altimmune i øjeblikket.

AlleAktien-kvalitetsscore for Altimmune er 3/10.

ISIN for Altimmune er US02155H2004. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Altimmune er A2N5Z6. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Altimmune er ALT. Tickersymbolet bruges til at handle Altimmune-aktier på børsen.

Dividendeudbytteprocenten for Altimmune er i øjeblikket 93,87 %.

Altimmune har udbetalt dividende hvert år i de seneste 0 år.

Altimmune er klassificeret i sektoren 'Sundhed'.

For at modtage den seneste dividende fra Altimmune fra på 2,91 USD, skulle du have aktien i din portefølje før ex-datoen den .

Sidste dividende blev udbetalt den .

Dividenderne fra Altimmune udloddes i USD.